首页/数据集/Suppl Table S4 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

Suppl Table S4 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

NIAID Data Ecosystem2026-05-02 收录

数据链接：

https://figshare.com/articles/dataset/Suppl_Table_S4_from_Targeting_CCL2_CCR2_Signaling_Overcomes_MEK_Inhibitor_Resistance_in_Acute_Myeloid_Leukemia/25826387 数据链接链接失效反馈

官方服务：

资源简介：

Correlation of trametinib AUC and AML feature annotations

应用场景：

创建时间：

2024-05-15

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

Ploidy variations between secondary resistant and parental soft-tissue sarcoma cell lines.

肿瘤耐药机制

细胞倍性分析

only sensitive cloneonly resistant clone-: absence of allelic imbalancePloidy variations between secondary resistant and parental soft-tissue sarcoma cell lines.

Figshare2015-12-03 更新50

Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction

肿瘤耐药机制

特定类别药物开发

Developing multifunctional platinum(IV) prodrugs via integrating bioactive pharmacophores into one entity is an attractive strategy to ameliorate the defects of platinum(II) drugs. Herein, a series

NIAID Data Ecosystem40

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

肿瘤耐药机制

信号通路靶向治疗

BackgroundThe sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the development of acquired resistance le

Figshare2016-01-18 更新50

Suppression of adaptive responses to targeted cancer therapy by transcriptional repression [RNA-seq]. Homo sapiens

肿瘤耐药机制

转录组药物响应

Large-scale genomic profiling efforts have facilitated the characterization of molecular alterations in cancers and aided the development of targeted kinase inhibitors for a wide array of cancer types

NIAID Data Ecosystem50

Suppl Table S4 from Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

资源简介：

相关数据集